Photodynamic	0	12	O
therapy	13	20	O
with	21	25	O
verteporfin	26	37	B-Drug_or_compound
for	38	41	O
subfoveal	42	51	O
choroidal	52	61	O
neovascularization	62	80	O
secondary	81	90	O
to	91	93	O
pathologic	94	104	O
myopia	105	111	O
:	111	112	O
long	113	117	O
-	117	118	O
term	118	122	O
study	123	128	O
.	128	129	O

PURPOSE	131	138	O
:	138	139	O
To	140	142	O
assess	143	149	O
the	150	153	O
safety	154	160	O
and	161	164	O
effectiveness	165	178	O
of	179	181	O
photodynamic	182	194	O
therapy	195	202	O
(	203	204	O
PDT	204	207	O
)	207	208	O
with	209	213	O
verteporfin	214	225	B-Drug_or_compound
for	226	229	O
subfoveal	230	239	O
choroidal	240	249	O
neovascularization	250	268	O
(	269	270	O
CNV	270	273	O
)	273	274	O
secondary	275	284	O
to	285	287	O
pathologic	288	298	O
myopia	299	305	O
(	306	307	O
PM	307	309	O
)	309	310	O
.	310	311	O

METHODS	312	319	O
:	319	320	O
Sixty	321	326	O
-	326	327	O
two	327	330	O
patients	331	339	B-Organism
(	340	341	O
62	341	343	O
eyes	344	348	B-Organ
)	348	349	O
with	350	354	O
PM	355	357	O
underwent	358	367	O
PDT	368	371	O
according	372	381	O
to	382	384	O
the	385	388	O
guidelines	389	399	O
of	400	402	O
the	403	406	O
Verteporfin	407	418	B-Drug_or_compound
in	419	421	O
Photodynamic	422	434	O
Therapy	435	442	O
Study	443	448	O
.	448	449	O

Clinical	450	458	O
evaluations	459	470	O
performed	471	480	O
at	481	483	O
all	484	487	O
study	488	493	O
visits	494	500	O
included	501	509	O
measurement	510	521	O
of	522	524	O
best	525	529	O
-	529	530	O
corrected	530	539	O
Snellen	540	547	O
visual	548	554	O
acuity	555	561	O
,	561	562	O
slit	563	567	O
-	567	568	O
lamp	568	572	O
biomicroscopy	573	586	O
,	586	587	O
and	588	591	O
fundus	592	598	B-Multi-tissue_structure
fluorescein	599	610	B-Drug_or_compound
angiography	611	622	O
.	622	623	O

Patients	624	632	B-Organism
were	633	637	O
followed	638	646	O
up	647	649	O
at	650	652	O
1	653	654	O
month	655	660	O
and	661	664	O
3	665	666	O
months	667	673	O
after	674	679	O
treatment	680	689	O
and	690	693	O
thereafter	694	704	O
at	705	707	O
3	708	709	O
-	709	710	O
month	710	715	O
intervals	716	725	O
.	725	726	O

RESULTS	727	734	O
:	734	735	O
The	736	739	O
final	740	745	O
visual	746	752	O
acuity	753	759	O
of	760	762	O
the	763	766	O
study	767	772	O
patients	773	781	B-Organism
,	781	782	O
after	783	788	O
a	789	790	O
median	791	797	O
follow	798	804	O
-	804	805	O
up	805	807	O
of	808	810	O
31	811	813	O
months	814	820	O
,	820	821	O
improved	822	830	O
by	831	833	O
greater	835	842	O
than	843	847	O
or	848	850	O
=	850	851	O
1	851	852	O
Snellen	853	860	O
lines	861	866	O
in	867	869	O
8	870	871	O
patients	872	880	B-Organism
(	881	882	O
13	882	884	O
%	884	885	O
)	885	886	O
,	886	887	O
deteriorated	888	900	O
in	901	903	O
20	904	906	O
(	907	908	O
32	908	910	O
%	910	911	O
)	911	912	O
,	912	913	O
and	914	917	O
remained	918	926	O
stable	927	933	O
in	934	936	O
34	937	939	O
(	940	941	O
55	941	943	O
%	943	944	O
)	944	945	O
.	945	946	O

The	947	950	O
baseline	951	959	O
visual	960	966	O
acuity	967	973	O
was	974	977	O
similar	978	985	O
in	986	988	O
the	989	992	O
various	993	1000	O
study	1001	1006	O
groups	1007	1013	O
.	1013	1014	O

The	1015	1018	O
final	1019	1024	O
mean	1025	1029	O
visual	1030	1036	O
acuity	1037	1043	O
in	1044	1046	O
group	1047	1052	O
A	1053	1054	O
(	1055	1056	O
55	1056	1058	O
years	1059	1064	O
of	1065	1067	O
age	1068	1071	O
or	1072	1074	O
younger	1075	1082	O
)	1082	1083	O
was	1084	1087	O
20	1088	1090	O
/	1090	1091	O
80	1091	1093	O
and	1094	1097	O
significantly	1098	1111	O
(	1112	1113	O
P	1113	1114	O
=	1114	1115	O
0	1115	1116	O
.	1116	1117	O
006	1117	1120	O
)	1120	1121	O
better	1122	1128	O
than	1129	1133	O
that	1134	1138	O
(	1139	1140	O
20	1140	1142	O
/	1142	1143	O
138	1143	1146	O
)	1146	1147	O
in	1148	1150	O
group	1151	1156	O
B	1157	1158	O
(	1159	1160	O
older	1160	1165	O
than	1166	1170	O
55	1171	1173	O
years	1174	1179	O
of	1180	1182	O
age	1183	1186	O
)	1186	1187	O
.	1187	1188	O

The	1189	1192	O
mean	1193	1197	O
final	1198	1203	O
visual	1204	1210	O
acuity	1211	1217	O
in	1218	1220	O
eyes	1221	1225	B-Organ
with	1226	1230	O
higher	1231	1237	O
refractive	1238	1248	O
error	1249	1254	O
at	1255	1257	O
baseline	1258	1266	O
(	1267	1268	O
greater	1268	1275	O
than	1276	1280	O
-	1281	1282	O
17	1282	1284	O
diopters	1285	1293	O
)	1293	1294	O
was	1295	1298	O
significantly	1299	1312	O
better	1313	1319	O
(	1320	1321	O
P	1321	1322	O
=	1322	1323	O
0	1323	1324	O
.	1324	1325	O
014	1325	1328	O
)	1328	1329	O
than	1330	1334	O
that	1335	1339	O
in	1340	1342	O
eyes	1343	1347	B-Organ
with	1348	1352	O
lower	1353	1358	O
refractive	1359	1369	O
error	1370	1375	O
(	1376	1377	O
-	1377	1378	O
6	1378	1379	O
to	1380	1382	O
-	1383	1384	O
10	1384	1386	O
diopters	1387	1395	O
)	1395	1396	O
.	1396	1397	O

CNV	1398	1401	O
size	1402	1406	O
did	1407	1410	O
not	1411	1414	O
affect	1415	1421	O
visual	1422	1428	O
outcomes	1429	1437	O
.	1437	1438	O

CONCLUSION	1439	1449	O
:	1449	1450	O
PDT	1451	1454	O
preserves	1455	1464	O
vision	1465	1471	O
in	1472	1474	O
patients	1475	1483	B-Organism
with	1484	1488	O
CNV	1489	1492	O
associated	1493	1503	O
with	1504	1508	O
PM	1509	1511	O
.	1511	1512	O

Younger	1513	1520	O
patients	1521	1529	B-Organism
and	1530	1533	O
eyes	1534	1538	B-Organ
with	1539	1543	O
higher	1544	1550	O
refractive	1551	1561	O
error	1562	1567	O
appear	1568	1574	O
more	1575	1579	O
likely	1580	1586	O
to	1587	1589	O
benefit	1590	1597	O
from	1598	1602	O
PDT	1603	1606	O
with	1607	1611	O
verteporfin	1612	1623	B-Drug_or_compound
.	1623	1624	O

